One of the goals of the Nurse Practitioner Society® of the DNA is to promote the dermatology nurse practitioner. The Nurse Practitioner Society® of the DNA is a component of the Dermatology Nurses’ Association comprised of 500+ nurse practitioners practicing in dermatology.
The DNA Annual Convention provides Dermatology Nurse Practitioners with focused sessions to help them improve their career goals and further their learning.
NP Forum Session Schedule
All general convention events and exhibit times are the same as posted on the daily general session schedules.
Thursday, March 26, 2026
Robin Weber Symposium: Updates in Psoriasis Management
GS210 8:00 AM - 9:00 AM
Speaker: Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, FSDNP
This session will provide a comprehensive overview of the management of psoriasis using an interactive, and fun case-based format. We will review the pathogenesis and clinical presentation of the many variants of psoriasis. We will identify and explain the immune-based targets that provide therapeutic targets, focusing on the newest psoriasis treatments. Finally, we will discuss patient education to enhance understanding and adherence to therapy and improved quality of life.
Learning Objectives:
The learner will be to identify 3 new therapeutic targetsfort the management of psoriasis.
ANCC CE 1.0 | Pharmacotherapeutics 0.5 - 30 Minutes
Speaker: Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, FSDNP
This session will provide a comprehensive overview of the management of psoriasis using an interactive, and fun case-based format. We will review the pathogenesis and clinical presentation of the many variants of psoriasis. We will identify and explain the immune-based targets that provide therapeutic targets, focusing on the newest psoriasis treatments. Finally, we will discuss patient education to enhance understanding and adherence to therapy and improved quality of life.
Learning Objectives:
The learner will be to identify 3 new therapeutic targetsfort the management of psoriasis.
ANCC CE 1.0 | Pharmacotherapeutics 0.5 - 30 Minutes
Acne Management
GS220 9:00 AM - 10:00 AM
Speaker: Carla Torres-Zegarra, MD
From Breakouts to Balance: Practical Acne Management provides a clear, evidence-based approach to diagnosing and treating acne across severity levels. Designed for clinical practice, this session equips healthcare professionals with practical treatment algorithms, tips for medication selection, and effective patient counseling strategies to improve adherence, manage side effects, and achieve better skin outcomes.
Learning Objectives:
Identify the key pathogenic factors of acne and use them to guide individualized, evidence-based treatment selection. Apply a stepwise, severity-based approacht o acne management using topical and systemic therapies. Implement effective patient counseling strategies to improve adherence, manage side effects,and set realistic expectations.
ANCC CE 1.0
Speaker: Carla Torres-Zegarra, MD
From Breakouts to Balance: Practical Acne Management provides a clear, evidence-based approach to diagnosing and treating acne across severity levels. Designed for clinical practice, this session equips healthcare professionals with practical treatment algorithms, tips for medication selection, and effective patient counseling strategies to improve adherence, manage side effects, and achieve better skin outcomes.
Learning Objectives:
Identify the key pathogenic factors of acne and use them to guide individualized, evidence-based treatment selection. Apply a stepwise, severity-based approacht o acne management using topical and systemic therapies. Implement effective patient counseling strategies to improve adherence, manage side effects,and set realistic expectations.
ANCC CE 1.0
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients With Certain Skin Diseases Driven in Part by Type 2 Inflammation
Lunch Symposium 11:45 AM - 1:00 PM
Speaker: Leigh Ann Pansch, MSN, FNP-BC, DCNP
Learn more about itch in patients with atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with skin diseases driven in part by Type 2 inflammation.
Supported by Regeneron and Sanofi
Speaker: Leigh Ann Pansch, MSN, FNP-BC, DCNP
Learn more about itch in patients with atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with skin diseases driven in part by Type 2 inflammation.
Supported by Regeneron and Sanofi
Managing Complications Following Mohs Micrographic Surgery
NP241 1:00 PM - 2:00 PM
Speaker: Aleksi Hendricks, MD
Overview of potential complications and strategies for outpatient management following Mohs micrographic surgery.
Learning Objectives:
Recognize common potential complications following Mohs surgery and initiate appropriate management.
ANCC CE 1.0
Speaker: Aleksi Hendricks, MD
Overview of potential complications and strategies for outpatient management following Mohs micrographic surgery.
Learning Objectives:
Recognize common potential complications following Mohs surgery and initiate appropriate management.
ANCC CE 1.0
Lichen Planus: Updates on Diagnosis and Treatments
NP251 3:00 PM - 4:00 PM
Speaker: Matthew Vesely, MD, PhD
This presentation provides an up-to-date overview of lichen planus, highlighting advances in understanding its pathogenesis and clinical variants. Dr. Vesely will discuss current and emerging treatment strategies—from topical and systemic immunomodulators to novel targeted therapies—emphasizing a practical, evidence-based approach to managing this challenging inflammatory skin disease.
Learning Objectives:
Describe updated pathogenesis of lichen planus, its subtypes and treatments.
ANCC CE 1.0 | Pharmacotherapeutics 0.5
Speaker: Matthew Vesely, MD, PhD
This presentation provides an up-to-date overview of lichen planus, highlighting advances in understanding its pathogenesis and clinical variants. Dr. Vesely will discuss current and emerging treatment strategies—from topical and systemic immunomodulators to novel targeted therapies—emphasizing a practical, evidence-based approach to managing this challenging inflammatory skin disease.
Learning Objectives:
Describe updated pathogenesis of lichen planus, its subtypes and treatments.
ANCC CE 1.0 | Pharmacotherapeutics 0.5
Cutaneous Lupus: Updates on Diagnosis and Treatments
NP261 4:00 PM - 5:00 PM
Speaker: Matthew Vesely, MD, PhD
This session will review recent progress in the diagnosis and management of cutaneous lupus erythematosus, integrating clinical, histopathologic, and molecular insights. Dr. Vesely will outline modern classification frameworks, discuss biomarkers guiding precision diagnosis, and present new therapeutic developments, including biologic and immune-targeted approaches designed to improve outcomes and quality of life for patients with lupus skin disease.
Learning Objectives:
Participants will be able to identify the subtypes of cutaneous lupus and emerging treatments.
ANCC CE 1.0 | Pharmacotherapeutics 0.5
Speaker: Matthew Vesely, MD, PhD
This session will review recent progress in the diagnosis and management of cutaneous lupus erythematosus, integrating clinical, histopathologic, and molecular insights. Dr. Vesely will outline modern classification frameworks, discuss biomarkers guiding precision diagnosis, and present new therapeutic developments, including biologic and immune-targeted approaches designed to improve outcomes and quality of life for patients with lupus skin disease.
Learning Objectives:
Participants will be able to identify the subtypes of cutaneous lupus and emerging treatments.
ANCC CE 1.0 | Pharmacotherapeutics 0.5
Advanced Practitioner Psoriasis Recognition Program (APReP)
5:30pm - 8:00pm
Speakers: Tomas Chao, PA-C - Atlanta North Dermatology Lakshi Aldredge, ANP, MSN, ANP-BC, DCNP - VA Hospital
Credit Designation: The National Psoriasis Foundation designates this live activity for a maximum of 2 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity. The National Psoriasis Foundation designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Psoriasis Foundation designates this live activity for a maximum of 2 Hour(s) NCPD (ANCC Contact Hours). Participants should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support: This activity is supported by independent educational grants from Johnson and Johnson Innovative Medicine, Lilly and UCB.
Accreditation Statement: The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Learning Objectives: At the conclusion of this activity, the participant will have increased competence related to:
• Discussing the pathophysiology of Psoriasis (PsO) and Psoriatic Arthritis (PsA), including the identification of targets for therapy
• Recognizing the clinical characteristics of PsO, PsA and associated comorbidities • Applying guideline-based criteria for the diagnosis and assessment of PsO and PsA
• Selecting appropriate therapies to treat and manage moderate to severe PsO based on current evidence for efficacy, safety, and adherence
• Classifying the spectrum of comorbidities associated with PsO and PsA
• Determining treatment plans aimed at minimizing the impact of associated comorbidities on health outcomes and quality of life
Other Comments: Dinner will be served at this event.
Register Online
Speakers: Tomas Chao, PA-C - Atlanta North Dermatology Lakshi Aldredge, ANP, MSN, ANP-BC, DCNP - VA Hospital
Credit Designation: The National Psoriasis Foundation designates this live activity for a maximum of 2 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity. The National Psoriasis Foundation designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Psoriasis Foundation designates this live activity for a maximum of 2 Hour(s) NCPD (ANCC Contact Hours). Participants should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support: This activity is supported by independent educational grants from Johnson and Johnson Innovative Medicine, Lilly and UCB.
Accreditation Statement: The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Learning Objectives: At the conclusion of this activity, the participant will have increased competence related to:
• Discussing the pathophysiology of Psoriasis (PsO) and Psoriatic Arthritis (PsA), including the identification of targets for therapy
• Recognizing the clinical characteristics of PsO, PsA and associated comorbidities • Applying guideline-based criteria for the diagnosis and assessment of PsO and PsA
• Selecting appropriate therapies to treat and manage moderate to severe PsO based on current evidence for efficacy, safety, and adherence
• Classifying the spectrum of comorbidities associated with PsO and PsA
• Determining treatment plans aimed at minimizing the impact of associated comorbidities on health outcomes and quality of life
Other Comments: Dinner will be served at this event.
Friday, March 27, 2026
Artificial Intelligence Enhances Skin Allergy Testing
GS310 8:00 AM - 9:00 AM
Speaker: Mikolaj A. Wieczorek, M.S.
Allergic contact dermatitis is an inflammatory skin response that affects about 1 in 5 people and is diagnosed using patch testing (PT). Traditional PT requires three in-person clinical appointments spread over 5 days using standardized allergen panels that are not tailored to a patient’s unique risk profile. The allergens are typically applied to the patient’s back, which necessitates that the test vehicle be removed and read by trained medical staff. This process creates long waits, specialist shortages, and substantial financial and logistical burdens for patients. Our personalized, AI-assisted approach reimagines PT by transitioning it from provider-led to patient-centered testing. Patches are placed on the volar forearm, allowing patients to easily access the test site and document reactions using a smartphone app. This solution expands access and reduces test burden while supporting providers through evidence-based allergen recommendations, AI-assisted interpretation, and automated documentation that together guide diagnosis.
Learning Objectives:
Describe key barriers in traditional patch testing workflows that affect access, cost, and documentation workload. Explain how an AI tool progresses from concept through clinical validation and phased early clinical implementation, using patch testing as an example. Understand the structure and outcomes of clinical trials evaluating AI-assisted, patient-centered patch testing, including how AI performance compares to human readers across different levels of medical training and variability. Discuss how AI-assisted patch testing may improve patient access, diagnostic accuracy, and clinical efficiency.
ANCC CE 1.0
Speaker: Mikolaj A. Wieczorek, M.S.
Allergic contact dermatitis is an inflammatory skin response that affects about 1 in 5 people and is diagnosed using patch testing (PT). Traditional PT requires three in-person clinical appointments spread over 5 days using standardized allergen panels that are not tailored to a patient’s unique risk profile. The allergens are typically applied to the patient’s back, which necessitates that the test vehicle be removed and read by trained medical staff. This process creates long waits, specialist shortages, and substantial financial and logistical burdens for patients. Our personalized, AI-assisted approach reimagines PT by transitioning it from provider-led to patient-centered testing. Patches are placed on the volar forearm, allowing patients to easily access the test site and document reactions using a smartphone app. This solution expands access and reduces test burden while supporting providers through evidence-based allergen recommendations, AI-assisted interpretation, and automated documentation that together guide diagnosis.
Learning Objectives:
Describe key barriers in traditional patch testing workflows that affect access, cost, and documentation workload. Explain how an AI tool progresses from concept through clinical validation and phased early clinical implementation, using patch testing as an example. Understand the structure and outcomes of clinical trials evaluating AI-assisted, patient-centered patch testing, including how AI performance compares to human readers across different levels of medical training and variability. Discuss how AI-assisted patch testing may improve patient access, diagnostic accuracy, and clinical efficiency.
ANCC CE 1.0
Infantile Hemangiomas
GS320 9:00 AM - 10:00 AM
Speaker: Sofia Guelfand Warnken, MD
Recognizing the most common vascular birthmarks in the pediatric population, identifying high-risk hemangiomas, and understanding their potential complications.
Learning Objectives:
Recognizing high risk infantile hemangiomas.
ANCC CE 1.0
Speaker: Sofia Guelfand Warnken, MD
Recognizing the most common vascular birthmarks in the pediatric population, identifying high-risk hemangiomas, and understanding their potential complications.
Learning Objectives:
Recognizing high risk infantile hemangiomas.
ANCC CE 1.0
NP Networking
10:00 AM - 10:30 AM
Improvement or Resolution of Psoriasis in Two Distinct Cases Following Autohemotherapy (AHT) or/and Plasma Rich Fibrin (PRF)
NP331 10:30 AM - 11:30 AM
Speakesr: Galina Warren, ANP, DCNP, MSN and Jessica Buzenas, MD
Our experience with Autohemotherapy (AHT) and Plasma-Rich Fibrin (PRF) as an alternative therapeutic approach to treatment of Psoriasis. AHT involves injecting a small amount of a patient's own blood, drawn from a vein, into gluteal muscle; thereby, triggering systemic immunomodulatory effects. PRF intralesional (IL) or subcutaneous (SQ) was used to augment AHT in case of extensive psoriatic plaques coverage.
Learning Objectives:
Describe how to evaluate the benefits, limitations, and safety considerations of autohemotherapy and PRF as a potential treatment modality for psoriasis.
ANCC CE 1.0
Speakesr: Galina Warren, ANP, DCNP, MSN and Jessica Buzenas, MD
Our experience with Autohemotherapy (AHT) and Plasma-Rich Fibrin (PRF) as an alternative therapeutic approach to treatment of Psoriasis. AHT involves injecting a small amount of a patient's own blood, drawn from a vein, into gluteal muscle; thereby, triggering systemic immunomodulatory effects. PRF intralesional (IL) or subcutaneous (SQ) was used to augment AHT in case of extensive psoriatic plaques coverage.
Learning Objectives:
Describe how to evaluate the benefits, limitations, and safety considerations of autohemotherapy and PRF as a potential treatment modality for psoriasis.
ANCC CE 1.0
Advances in Dermatologic Therapeutics: From Chronic Urticaria to Alopecia and Beyond
NP351 1:00 PM - 2:00 PM
Speaker: Christopher Bunick, MD, Ph.D.
Speaker: Christopher Bunick, MD, Ph.D.
Case Conundrums: Confusing Cutaneous "Skin-erios" in Kids
NP361 2:00 PM - 3:00 PM
Speakers: Alann Bree, MD and Joseph Lam, MD
Have you ever been stumped by a clinical scenario when caring for a pediatric dermatology patient? Then this session is for you. The presenters will review perplexing cases from their careers as well as confusing cases submitted by conference attendees.
Learning Objectives:
Describe how to develop differential diagnoses for a patient presenting with confusing signs and symptoms. Discuss common referrals that can be easily recognized and managed. List benign and distinctive eruptions in children.
ANCC CE 1.0 | Pharmacotherapeutics 0.8 - 5 minutes
Speakers: Alann Bree, MD and Joseph Lam, MD
Have you ever been stumped by a clinical scenario when caring for a pediatric dermatology patient? Then this session is for you. The presenters will review perplexing cases from their careers as well as confusing cases submitted by conference attendees.
Learning Objectives:
Describe how to develop differential diagnoses for a patient presenting with confusing signs and symptoms. Discuss common referrals that can be easily recognized and managed. List benign and distinctive eruptions in children.
ANCC CE 1.0 | Pharmacotherapeutics 0.8 - 5 minutes
Diagnostic Pearls: More Than Skin Deep
NP371 3:15 PM - 4:15 PM
Speaker: Alann Bree, MD
Skin disease is associated with significant psychosocial impacts. This session will summarize these impacts, how to assess them, and how to best address them as a dermatology practitioner who is committed to holistic patient care.
Learning Objectives:
Identify how to assess psychosocial issues related to skin disease.
ANCC CE 1.0
Speaker: Alann Bree, MD
Skin disease is associated with significant psychosocial impacts. This session will summarize these impacts, how to assess them, and how to best address them as a dermatology practitioner who is committed to holistic patient care.
Learning Objectives:
Identify how to assess psychosocial issues related to skin disease.
ANCC CE 1.0
Diagnosis at Your Fingertips
NP381 4:15 PM - 5:15 PM
Speaker: Joseph Lam, MD
Many pediatric dermatological conditions exist that can be difficult to recognize. This session will review simple tools (including fingertips, otoscope, & diascopy) to assist the learner in recognizing pilomatricomas, spider angiomas, mastocytomas, congenital smooth muscle hemartomas and terra firma-forme dermatosis.
Learning Objectives:
Describe skin diseases that can be identified with yourfingers (and office tools).
ANCC CE 1.0 | Pharmacotherapeutics 0.8 - 5 minutes
Speaker: Joseph Lam, MD
Many pediatric dermatological conditions exist that can be difficult to recognize. This session will review simple tools (including fingertips, otoscope, & diascopy) to assist the learner in recognizing pilomatricomas, spider angiomas, mastocytomas, congenital smooth muscle hemartomas and terra firma-forme dermatosis.
Learning Objectives:
Describe skin diseases that can be identified with yourfingers (and office tools).
ANCC CE 1.0 | Pharmacotherapeutics 0.8 - 5 minutes